Upcoming events
BioJapan 2024
In person
For the first time, ZoBio is excited to participate in BioJapan 2024, an event held in conjunction with Regenerative Medicine Japan and healthTECH Japan. As Asia’s largest partnering event, it offers a comprehensive platform through its three main programs: exhibition, seminars, and partnering.
Jan Schultz will be attending One-on-One meetings to share insights about our services and recent developments at ZoBio and ODS with other participants.
15th Swiss Course on Medicinal Chemistry in Leysin
In person
As in previous years, ZoBio is proud to be a sponsor of the 15th Swiss Course on Medicinal Chemistry in Leysin!
This five-day Medicinal Chemistry School, organized by the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society , focuses on the most cutting-edge aspects of small molecule drug discovery, highlighting methodologies and technologies that support hit generation, lead finding, and lead optimization campaigns.
The course content is tailored for young scientists working in medicinal chemistry, as well as those from related disciplines such as biochemistry, pharmacy, pharmacology, or biophysics, from both the pharmaceutical and biotech industries.
ZoBio is excited to contribute to this special event. On Thursday, October 17th, our scientist Stephan Theisgen will present a talk on the application of NMR in modern drug discovery. Additionally, Marta Carneiro (Head of Structural Biology) and Johan Veerman (Head of Chemistry) will share their expertise on the use of biophysics in various aspects of drug discovery with the next generation of drug hunters.
We are confident it will be another unforgettable event!
Past events
Discovery on Target
In person
Our team was excited to participate in Discovery on Target, the industry’s premier event focused on novel drug targets and cutting-edge technologies for drug discovery professionals. The conference always showcase the latest advancements in both current and emerging “hot” targets, as well as innovative target validation strategies for developing novel therapeutic agents, from biologics to small molecules.
Masa Kobayashi, Head of Assay Development and Screening, presented the poster titled Site Selective Screening: Using Biophysics to Define a Mode of Action.
Fragment-Based Lead Discovery Conference
In person
This year, the FBLD Conference was held in Boston, and ZoBio was excited to be part of this remarkable event. Fragment-Based Lead Discovery (FBLD) continues to grow rapidly as a multidisciplinary field, bringing together experts in chemistry, biochemistry, and related areas to present the latest advancements. We couldn’t miss the opportunity to be there!
Gregg Siegal, CEO of ZoBio, enjoyed connecting with the FBLD community and participating in a high-quality program featuring talks, workshops, poster sessions, and numerous networking opportunities, all centered around the diverse aspects of fragment-based drug discovery.
Developments in Protein Interaction Analysis (DiPIA 2024)
In person
From September 9 to 12, Welmoet de Winter, one of our scientists, was attending the DiPIA conference in Uppsala, Sweden. DiPIA, or Developments in Protein Interaction Analysis, is a global scientific conference hosted by Cytiva. This event brings together industry peers to share best practices, research, and new applications in the field. The conference is specifically dedicated to surface plasmon resonance (SPR) technology, as featured in our Biacore™ SPR systems.
The theme for this year’s DiPIA was Exploring the Unknown, focusing on the past, present, and future of scientific exploration.
Welmoet presented the poster: Mechanism of action: selective screen of small molecules by SPR. She truly enjoyed the vibrant exchange of knowledge and innovation at this great event.